Michael Grever R. MD

Michael Grever R. MD
ChairCollege of Medicinegrever.1@osu.edu
Room 392 Twelfth Avenue, 395 West 395 W 12th Avenue Columbus Ohio 43210
Phone:614-293-8724Fax: (614) 293-6656
  • Administrative
  • Leukemia Research

Research Description

Dr. Grever has over 30 years of experience in experimental chemotherapy and drug development for patients with CLL and other hematologic malignancies. Dr. Grever performed the initial phase I studies on purine nucleoside analogs in patients with hematologic malignancies, and conducted one of the initial phase II studies of fludarabine in patients with CLL. Together with Dr. Byrd, Dr. Grever was among the first to investigate the potential both of histone deacetylase inhibitors (depsipeptide) and cyclin-dependent kinase inhibitors (flavopiridol) in CLL, and oversaw both laboratory and Phase I clinical studies of both these agents.

Current Publications

  • Grever MR, Blachly JS, Andritsos LAHairy cell leukemia: Update on molecular profiling and therapeutic advances.Blood Rev 28 197-203 9/1/2014
  • Lena RJ, Doykan C, Blake N, Elashoff M, Hoff DV, Bearss DJ, Cardone MH, Andritsos L, Byrd JC, Lanasa MC, Grever MR, Johnson AJ, Pierceall WE, Warner SLMitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response.Leukemia in press 7/3/2014
  • Byrd JC, Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC, Rassenti LZ, Greaves AW, Geyer S, Wierda WG, Brown JR, Gribben JG, Barrientos JC, Rai KR, Kay NE, Kipps TJ, Shields P, Zhao W, Grever MR, Plass CValidation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.Blood 124 42-8 7/3/2014
  • Walker AR, Klisovic RB, Garzon R, Schaaf LJ, Humphries K, Devine SM, Byrd JC, Grever MR, Marcucci G, Blum WPhase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.Leuk Lymphoma 55 1304-8 6/1/2014
  • Stephens DM, Ruppert AS, Jones JA, Woyach J, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JCImpact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center.Leukemia 28 1365-8 6/1/2014
  • Klisovic RB, Blum W, Liu Z, Xie Z, Kefauver C, Huynh L, Zwiebel JA, Devine SM, Byrd JC, Grever MR, Chan KK, Marcucci GPhase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.Leuk Lymphoma 55 1332-6 6/1/2014
  • Callahan KP, Minhajuddin M, Corbett C, Lagadinou ED, Rossi RM, Grose V, Balys MM, Pan L, Jacob S, Frontier A, Grever MR, Lucas DM, Kinghorn AD, Liesveld JL, Becker MW, Jordan CTFlavaglines target primitive leukemia cells and enhance anti-leukemia drug activity.Leukemia in press 2/28/2014
  • Hofmeister CC, Poi M, Bowers MA, Zhao W, Phelps MA, Benson DM, Kraut EH, Farag S, Efebera YA, Sexton J, Lin TS, Grever M, Byrd JCA phase I trial of flavopiridol in relapsed multiple myeloma.Cancer Chemother Pharmacol 73 249-57 2/1/2014
  • Grever MRHairy cell: young living longer but not cured.Blood 123 150-1 1/9/2014
  • Jones JA, Rupert AS, Poi M, Phelps MA, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JCFlavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.Am J Hematol 89 19-24 1/1/2014
  • Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd JC, Flynn JMCyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.Leuk Res 37 1195-9 10/1/2013
  • Walker AR, Klisovic R, Johnston JS, Jiang Y, Geyer S, Blum KA, Blum W, Kefauver C, Binkley P, Byrd JC, Grever MR, Garzon R, Phelps MA, Marcucci GPharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.Leuk Lymphoma 54 1996-2002 9/1/2013
  • Poi MJ, Hofmeister CC, Johnston JS, Edwards RB, Jansak BS, Lucas DM, Farag SS, Dalton JT, Devine SM, Grever MR, Phelps MAStandard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.Clin Pharmacokinet 52 705-12 8/1/2013
  • Zhou BS, Liu X, Deam D, Monk JP, Hicks WJ, Yen Y, Otterson GA, Grever MR, Bekaii-Saab T, Mortazavi A, Ling Y, Martin LK, Wei L, Phelps MA, Liu Z, Harper EJ, Ivy SP, Wu XA phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.Invest New Drugs 31 685-95 6/1/2013
  • Mould DR, Blum KA, Ji J, Ruppert AS, Poi M, Zhao Y, Johnson AJ, Byrd JC, Grever MR, Phelps MAA pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.Clin Cancer Res 19 1269-80 3/1/2013
  • Grever MRAccelerating safe drug development: an ideal approach to approval.Hematology Am Soc Hematol Educ Program 2013 24-9 1/1/2013
  • Kogure T, Kinghorn AD, Yan I, Bolon B, Lucas DM, Grever MR, Patel TTherapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer.PLoS One 8 e76136 1/1/2013
  • Grever MR, Kraut EH, Martin LK, Bekaii-Saab T, Serna D, Monk P, Clinton SKA phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors.Onkologie 36 657-60 1/1/2013
  • Chu BF, Karpenko MJ, Liu Z, Aimiuwu J, Villalona-Calero MA, Chan KK, Grever MR, Otterson GAPhase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer.Cancer Chemother Pharmacol 71 115-21 1/1/2013
  • Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Saradhi UV, Liu Z, Schwind S, Mims A, Byrd JC, Grever MR, Villalona-Calero MA, Klisovic R, Walker A, Garzon R, Blum W, Chan KK, Marcucci GIn vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia.AAPS J 15 242-9 1/1/2013
  • Nicholas C, Yang J, Peters SB, Bill MA, Baiocchi RA, Yan F, Sïf S, Tae S, Gaudio E, Wu X, Grever MR, Young GS, Lesinski GBPRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1.).PLoS One 8 e74710 1/1/2013
  • Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci GSilvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.J Hematol Oncol 6 21 1/1/2013
  • Peng Y, Wu LC, Xie Z, Deng Y, Hughes T, He S, Mo X, Chiu M, Wang QE, He X, Liu S, Grever MR, Chan KK, Liu Z, Yu JCurcumin down-regulates DNA methyltransferase 1 and plays an anti-leukemic role in acute myeloid leukemia.PLoS One 8 e55934 1/1/2013
  • Smith LL, Wagner AJ, Hessler J, Gupta S, Flynn J, Jones J, Johnson AJ, Yeh YY, Zhang X, Bannerji R, Grever MR, Byrd JCThe novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells.Leukemia 26 2554-7 12/1/2012
  • Martin LK, Grecula J, Jia G, Wei L, Yang X, Otterson GA, Wu X, Harper E, Kefauver C, Zhou BS, Yen Y, Bloomston M, Knopp M, Ivy SP, Grever M, Bekaii-Saab TA dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer.Int J Radiat Oncol Biol Phys 84 e475-81 11/15/2012
  • Heerema NA, Bingman A, Flynn JM, Grever MR, Jones JA, Elder P, Devine SM, Byrd JC, Andritsos LA, Jaglowski SM, Ruppert ASComplex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia.Br J Haematol 159 82-7 10/1/2012
  • Caligiuri MA, Bundschuh R, Marcucci G, Yan P, Frankhouser D, Murphy M, Tam HH, Rodriguez B, Curfman J, Trimarchi M, Geyer S, Wu YZ, Whitman SP, Metzeler K, Walker A, Klisovic R, Jacob S, Grever MR, Byrd JC, Bloomfield CD, Garzon R, Blum WGenome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.Blood 120 2466-74 9/20/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu